Form 4: Cidara CFO Sells Shares in Merck Merger

Cidara Therapeutics' CFO, Frank Karbe, disposed of all his common stock, restricted stock units, and stock options as part of the company's acquisition by Merck Sharp & Dohme LLC for $221.50 per common share.

Summary

• Cidara Therapeutics, Inc. was acquired by Merck Sharp & Dohme LLC, through its wholly-owned subsidiary Caymus Purchaser, Inc., with the merger becoming effective on January 7, 2026.
• Frank Karbe, Chief Financial Officer of Cidara, disposed of all his beneficial ownership in the company as a result of the merger.
• Common shares were acquired at a cash price of $221.50 per share.
• Series A Convertible Voting Preferred Stock was acquired at a cash price of $15,505.00 per share.
• Restricted Stock Units (RSUs) were cancelled and converted into cash at $221.50 per underlying common share.
• Employee Stock Options became fully vested and exercisable, then were cancelled and converted into cash based on the difference between the merger price ($221.50) and the option exercise price ($20.50).
• Karbe disposed of 7,526 common shares and 43,125 shares related to RSUs.
• Karbe also disposed of 115,000 employee stock options.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a merger where Cidara Therapeutics was acquired by Merck at a significant cash premium for its shareholders and option holders, indicating a very positive outcome for the company's equity stakeholders.

Positives

• Successful completion of the merger with Merck, indicating a definitive positive outcome for shareholders.
• Common shareholders received a significant cash consideration of $221.50 per share.
• Series A Preferred shareholders received $15,505.00 per share in cash.
• Employee stock options became fully vested and exercisable, allowing holders to realize value from their equity awards.

Negatives

• Cidara Therapeutics, Inc. ceases to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Merck.
• Existing shareholders no longer participate in the future growth or potential upside of Cidara as a standalone company.

Future Outlook

NA

Industry Context

The acquisition of Cidara Therapeutics by Merck reflects a broader trend in the pharmaceutical and biotechnology industry where larger established companies acquire smaller, innovative firms to bolster their pipelines, gain access to new technologies, or eliminate competition. This particular transaction indicates Merck's strategic interest in Cidara's assets or capabilities.

Stakeholder Impact

• Shareholders: Received significant cash consideration for their shares, concluding their investment in Cidara as an independent entity.
• Employees: Those with stock options and RSUs realized cash value from their equity awards. Future employment and compensation structures will be under Merck.
• Customers/Suppliers: Cidara's operations will continue as a Merck subsidiary, potentially leading to integration with Merck's existing supply chains and customer base.

Next Steps

• Cidara Therapeutics, Inc. will operate as a wholly-owned subsidiary of Merck Sharp & Dohme LLC.
• The reporting person, Frank Karbe, no longer holds beneficial ownership in Cidara Therapeutics as a publicly traded entity.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Merck, Merger, Acquisition, Form 4, Insider Transaction, Frank Karbe, Chief Financial Officer, Stock Options, Restricted Stock Units, Tender Offer